Cannabinoids pharmacology
Pro Research Analysisby 
Searched over 200M research papers for "cannabinoids pharmacology"
Cannabinoid Receptors and Endocannabinoid System Pharmacology
Cannabinoids exert their effects primarily through two main receptors: CB1 and CB2, both of which are G protein-coupled receptors. CB1 receptors are mainly found in the nervous system and are responsible for inhibiting neurotransmitter release, while CB2 receptors are mostly present on immune cells and modulate immune responses such as cytokine release 110. The discovery of these receptors, along with their endogenous ligands (endocannabinoids), has been central to understanding the pharmacology of cannabinoids and their roles in health and disease 1310.
Major and Minor Phytocannabinoids: Pharmacological Actions
The most studied plant cannabinoids (phytocannabinoids) are delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). THC acts as a partial agonist at both CB1 and CB2 receptors, producing psychoactive effects and modulating pain, appetite, and anxiety. CBD, in contrast, does not cause intoxication and acts as an antagonist or negative allosteric modulator at these receptors, with additional effects on immune cell migration and other molecular targets 259. Other minor cannabinoids, such as tetrahydrocannabivarin (THCV), cannabigerol (CBG), and cannabichromene (CBC), also interact with CB1 and CB2 receptors, often as partial agonists or antagonists, and may have unique therapeutic properties 35.
Beyond CB1 and CB2: Polypharmacology and Additional Targets
Cannabinoids, especially CBD and minor cannabinoids, have a broad range of molecular targets beyond CB1 and CB2 receptors. These include transient receptor potential (TRP) channels, peroxisome proliferator-activated receptors (PPARs), serotonin 5-HT1a receptors, and others. This polypharmacology underlies their diverse therapeutic effects, such as anti-inflammatory, neuroprotective, and anticonvulsant actions 39. The ability of cannabinoids to activate or inhibit multiple signaling pathways may also contribute to synergistic effects when different cannabinoids are used together .
Synthetic Cannabinoids: Potency and Toxicology
Synthetic cannabinoids are a diverse group of compounds designed to mimic the effects of natural cannabinoids but often have much higher potency at CB1 and CB2 receptors. These substances can produce stronger psychoactive effects and have been associated with significant toxicity, including severe intoxications and fatalities. Understanding their pharmacodynamics and toxicodynamics is crucial for public health and regulatory efforts .
Therapeutic Applications and Clinical Evidence
Cannabinoid-based medicines have been developed for a range of conditions, including chronic pain, epilepsy, multiple sclerosis, and chemotherapy-induced nausea. Clinical evidence supports the efficacy of specific cannabinoids for certain indications: CBD for epilepsy and Parkinsonism, dronabinol and nabiximols for chronic pain, appetite stimulation, and spasticity, among others. However, the strength of evidence varies depending on the cannabinoid and the condition being treated . Cannabinoid pharmacology is also being explored for neurodegenerative diseases, with preclinical studies suggesting potential benefits in conditions like Alzheimer’s, Parkinson’s, and Huntington’s diseases .
Advances in Cannabinoid Receptor Modulation
Recent research has focused on the development of selective agonists, antagonists, and allosteric modulators for CB1 and CB2 receptors. Allosteric modulators, which bind to sites distinct from the main active site, can fine-tune receptor activity and may offer new therapeutic strategies with fewer side effects. The identification of allosteric sites on CB1 receptors has opened new avenues for drug discovery and the development of next-generation cannabinoid-based therapies 810.
Conclusion
Cannabinoid pharmacology is complex and involves a wide array of natural and synthetic compounds acting on multiple molecular targets. The endocannabinoid system plays a significant role in both health and disease, and ongoing research continues to reveal new therapeutic opportunities for cannabinoids in various medical conditions. Understanding the diverse actions of cannabinoids at CB1, CB2, and other targets is essential for the development of safe and effective cannabinoid-based medicines 1234+6 MORE.
Sources and full results
Most relevant research papers on this topic